Evidence map›Paper›PMID 33284109›Full record

ArticleeLife2020

FLEXIQuant-LF to quantify protein modification extent in label-free proteomics data.

Christoph N Schlaffner, Konstantin Kahnert, Jan Muntel, Ruchi Chauhan, Bernhard Y Renard, Judith A Steen, Hanno Steen

Abstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christoph N Schlaffner *F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States.ORCID 0000-0003-2717-3406
Konstantin Kahnert *Department of Pathology, Boston Children's Hospital, Boston, United States.ORCID 0000-0002-8454-4894
Jan Muntel *Department of Pathology, Boston Children's Hospital, Boston, United States.ORCID 0000-0003-2320-5829
Ruchi ChauhanF.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States.
Bernhard Y RenardBioinformatics Unit (MF1), Robert Koch Institute, Berlin, Germany.
Judith A SteenF.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States.
Hanno SteenDepartment of Pathology, Boston Children's Hospital, Boston, United States.ORCID 0000-0003-0179-6648

Funding

Chemical Inhibitors to Define an Essential M. Tuberculosis Signaling NetworkR01AI099204 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUSSON, ROBERT N · 2012 to 2016
$6.1M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphomaR01CA196703 · NCI · BOSTON CHILDREN'S HOSPITAL · PI CHIARLE, ROBERTO · 2015 to 2025
$4.1M
Quantifying post-translational modifications and protein expression by HTP-MSRC4GM096319 · NIGMS · HARVARD MEDICAL SCHOOL · PI KIRSCHNER, MARC WALLACE · 2010 to 2010
$3.8M
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivoU01AI124284 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2016 to 2020
$2.9M
Proteogenomics to characterize novel non-coding and extragenic translationR01GM112007 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI KREIMAN, GABRIEL, STEEN, JUDITH A · 2015 to 2018
$2.4M
Regulation of SMN and Identification of its Downstream TargetR01NS066973 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI STEEN, JUDITH A · 2010 to 2014
$2.2M
Orbitrap Velos with ETD for Wayne State ProteomicsS10OD010700 · OD · WAYNE STATE UNIVERSITY · PI STEMMER, PAUL M · 2012 to 2012
$575k
NCI NIH HHS R01 CA196703NIAID NIH HHS R01 AI099204NIAID NIH HHS U01 AI124284NICHD NIH HHS U54 HD090255NIGMS NIH HHS R01 GM112007NIGMS NIH HHS RC4 GM096319NIH HHS S10 OD010700NINDS NIH HHS R01 NS066973
6 · The paper itself

Abstract

Improvements in LC-MS/MS methods and technology have enabled the identification of thousands of modified peptides in a single experiment. However, protein regulation by post-translational modifications (PTMs) is not binary, making methods to quantify the modification extent crucial to understanding the role of PTMs. Here, we introduce FLEXIQuant-LF, a software tool for large-scale identification of differentially modified peptides and quantification of their modification extent without knowledge of the types of modifications involved. We developed FLEXIQuant-LF using label-free quantification of unmodified peptides and robust linear regression to quantify the modification extent of peptides. As proof of concept, we applied FLEXIQuant-LF to data-independent-acquisition (DIA) data of the anaphase promoting complex/cyclosome (APC/C) during mitosis. The unbiased FLEXIQuant-LF approach to assess the modification extent in quantitative proteomics data provides a better understanding of the function and regulation of PTMs. The software is available at https://github.com/SteenOmicsLab/FLEXIQuantLF.

Indexed as

SoftwareAlgorithmsHeLa CellsHumansLinear ModelsPeptidesProteomicsPeptidesbiochemistrychemical biologycomputational biologyhumanlabel-free quantificationmass spectrometrymodification stoichiometrypeptide modificationPTM identificationPTM quantificationsystems biology

Identifiers

PMID33284109
PMCPMC7721442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.